Among mesenchymal stem cells: for the best therapy after ischemic stroke.
Among mesenchymal stem cells: for the best therapy after ischemic stroke.
复制标题
DOI：
10.1186/scrt157
复制
发表时间：
2013-01-31
影响因子：
7.5
通讯作者：
Ikegame Y
中科院分区：
文献类型：
--
作者：
Ikegame Y
间充质干细胞具有其他细胞无法比拟的优势，是缺血性卒中后干细胞治疗的最有前景的工具之一。间充质干细胞可以从各种来源获得。因此，需要对这些细胞进行广泛细致的比较研究，从临床前阶段(体外和体内)到临床阶段，以开发具有最合适细胞类型的最佳治疗方法。本期《干细胞研究与治疗》中的一项体内研究比较了从骨髓和脂肪组织中获得的两种细胞在啮齿动物中风模型中的治疗潜力。这篇评论讨论了间充质干细胞比较研究的意义，包括翻译研究中的相关文章。
Owing to the several advantages that they have over other cells, mesenchymal stem cells are among the most promising tools in stem cell therapy after ischemic stroke. Mesenchymal stem cells can be obtained from various sources. Therefore, a wide range of careful comparative studies of these cells is required, from the preclinical stage (in vitro and in vivo) to the clinical stage, in order to develop the best therapy with the most appropriate cell type. An in vivo study in this issue of Stem Cell Research & Therapy compares the therapeutic potential of two cell types, obtained from bone marrow and adipose tissue, in a rodent stroke model. This commentary discusses the significance of comparative studies of mesenchymal stem cells, including the related article in translational research.